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n the Speakers’ Bureauhe aim of this study was to report the short-term and long-term clinical impact of stent thrombosis (ST) and graft
occlusion (GO) in theﬁnal 5-year outcomesof theSYNTAX (SYNergyBetweenPCIWith TAXUSandCardiacSurgery) trial.Background The clinical effect of newer-generation drug-eluting stents and operative factors in complex coronary artery disease
is uncertain.Methods The incidence of 5-year ST and GO, and their association with clinical outcomes, were analyzed in the randomized
percutaneous coronary intervention and coronary artery bypass graft cohorts. ST and GO were deﬁned by the
SYNTAX protocol deﬁnitions (clinical presentation with acute coronary syndrome and angiographic/pathological
evidence), the Academic Research Consortium (ARC) deﬁnition for ST, and the newly devised “ARC-like” deﬁnition of
GO (i.e., deﬁnite, probable, or possible GO).Results At 5 years, 871 of 903 patients (96.5%) in the percutaneous coronary intervention cohort and 805 of 897 patients
(89.7%) in the coronary artery bypass graft cohort completed follow-up. As compared with other vessel locations,
protocol ST (72 lesions) occurred more frequently in the left main (14 of 72; 19%) and proximal coronary vasculature
(37 of 72; 51%) andprotocol GO (41 lesions) with grafts anastomosed to the distal right coronary artery (17 of 41; 42%).
The incidence of 5-year ARCdeﬁnite ST andARC-like deﬁnite GOdid not signiﬁcantly differ (7% [n¼ 48] vs. 6% [n¼ 32],
log rank p¼ 0.34); landmark analyses indicated signiﬁcantly increased ARC deﬁnite ST within 30 days (3% [n¼ 19] vs.
1% [n ¼ 6], log rank p ¼ 0.033) but not>30 days to 5 years (4.2% [n ¼ 29] vs. 4.5% [n ¼ 26], log rank p ¼ 0.78). At
presentation, ARC deﬁnite ST (n ¼ 48) and ARC-like deﬁnite GO (n ¼ 32) were adjudicated to be linked to 4 (8%) and
0 deaths, respectively. At 5 years, ARC deﬁnite ST (n¼ 48) and ARC deﬁnite/probable ST (n¼ 75) were associated with
17 (17 of48, 35.4%;median days to death: 0 days; interquartile range: 0 to 16days;maximum:321days) and31 (31 of
75, 41.3%; median: 0 days; interquartile range: 0 to 9 days; maximum: 721 days) cardiac deaths, respectively. At 5
years, ARC-like deﬁnite GO (n ¼ 32) and ARC-like deﬁnite/probable GO (n ¼ 53) were associated with 0 and 12 (12
of 52, 23.1%; median: 0 days; interquartile range: 0 to 14 days; maximum: 257 days) cardiac deaths, respectively.Conclusions Although the incidence of ST and GO was similar at 5 years, the clinical impact of ST appeared greater, with
a negative impact on short-term to long-term mortality. (J Am Coll Cardiol 2013;62:2360–9) ª 2013 by the
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December 24, 2013:2360–9 Stent Thrombosis and Graft Occlusion in the SYNTAX TrialAbbreviations
and Acronyms
ARC = Academic Research
Consortium
CABG = coronary artery
bypass graft
CEC = clinical events
committee
GO = graft occlusion
KM = Kaplan-Meier
LAD = left anterior
descending artery
LIMA = left internal
mammary artery
MI = myocardial infarction
PCI = percutaneous coronary
interventionThe ﬁnal 5-year reporting of the SYNTAX (SYNergy
Between PCI With TAXUS and Cardiac Surgery) trial
showed that coronary artery bypass graft (CABG) surgery
remained the standard of care for patients with complex (left
main or 3-vessel) coronary artery disease compared with
percutaneous coronary intervention (PCI) with ﬁrst-
generation drug-eluting stents (1,2). In subjects with lesser
complex coronary artery disease undergoing PCI, using the
anatomic SYNTAX Score to assess coronary artery
complexity (3) or the SYNTAX Score augmented with
clinical factors (SYNTAX Score II), (4,5) were shown to be
an acceptable alternative to CABG.
The clinical impact of stent thrombosis (ST) and graft
occlusion (GO) in the SYNTAX trial is unreported. The
purpose of the study was to report the incidence, timing,
predictors, and clinical impact of ST and GO in the
SYNTAX trial.RIMA = right internal
mammary artery
ST = stent thrombosis
ULMCA = unprotected left
main coronary arteryMethods
The SYNTAX trial is a randomized, prospective, multi-
center, “all-comers” trial investigating subjects with un-
protected left main coronary artery (ULMCA) disease
(isolated or associated with 1-, 2-, or 3-vessel disease) or de
novo 3-vessel disease and has previously been described
(1,2). In total, 1,800 subjects were randomized on a 1:1
basis to either PCI with Taxus Express paclitaxel-elutingTable 1 SYNTAX Protocol and ARC/ARC-Like Deﬁnitions of ST and G
Stent Thrombosis
SYNTAX protocol deﬁnition
The occurrence of any of the following:
1. Clinical presentation of acute coronary syndrome with ST conﬁrmed by
angiography, multi-slice CT, or autopsy
a. Angiographic documentation of a complete occlusion (TIMI ﬂow grade
0 or 1) of a previously successfully treated artery (TIMI ﬂow gade 2 to 3
immediately after stent placement and diameter stenosis 30) and/or
b. Documentation by angiography, multi-slice CT, or autopsy of ﬂow-limiting
thrombus or complete luminal obstruction within or adjacent to
a previously successfully treated lesion
2. Q-wave MI in the territory of one or more of the treated vessels (LAD, LCX,
RCA) within the ﬁrst 30 days (acute or subacute)
ARC deﬁnite ST
1. Angiographic or pathological conﬁrmation of partial or total thrombotic occlu-
sion within the peri-stent region and at least one of the following additional
criteria:
a. Acute ischemic symptoms
b. Ischemic electrocardiographic changes
c. Elevated cardiac biomarkers
ARC probable ST
1. Any unexplained death within 30 days of stent implantation
2. Any MI that is related to documented acute ischemia in the territory of the
implanted stent without angiographic conﬁrmation of ST
ARC possible ST
1. Any unexplained death beyond 30 days
*The deﬁnitions of protocol GO and ARC-like deﬁnite GO were identical. yBecause subjects had left main
disease or the left coronary system for unprotected left main coronary artery disease without subsequen
identical to ARC-like possible ST.
ARC ¼ Academic Research Consortium; CT ¼ computed tomography; GO ¼ graft occlusion; MI ¼ myo
coronary artery; ST ¼ stent thrombosis; TIMI ¼ Thrombolysis in Myocardial Infarction.stents (Boston Scientiﬁc Cor-
poration, Natick, Massachusetts)
or CABG.
An independent clinical events
committee (CEC), including car-
diologists, cardiac surgeons, and
a neurologist, reviewed all the
primary clinical endpoints and
ST/GO events. All deaths were
subdivided into cardiovascular and
noncardiovascular deaths by the
CEC. Cardiac deaths were clas-
siﬁed as related or unrelated to
a cardiac procedure by the CEC.
STandGO.Because theSYNTAX
trial began before publication of
the Academic Research Con-
sortium (ARC) deﬁnition, (6)
the SYNTAX trial instigated
a protocol deﬁnition for ST and
GO (Table 1). Subsequently, the
ARC criteria (6) for ST were
implemented and reported by a
separate CEC (see the Acknowledgments section). To allow
comparisons of ARC ST events to GO, “ARC-like” deﬁ-
nitions were formulated for GO (i.e., deﬁnite, probable, or
possible GO) using adapted ARC deﬁnitions (Table 1).O
Graft Occlusion
SYNTAX protocol deﬁnition
The occurrence of any of the following:
1. Clinical presentation of acute coronary syndrome with GO conﬁrmed by
angiography, multi-slice CT, or autopsy
a. Angiographic documentation of occlusion (TIMI ﬂow grade 0 or 1) of
a vascular graft and/or
b. Documentation by angiography, multi-slice CT, or autopsy of ﬂow-limiting
thrombus or complete luminal obstruction within a bypass graft or a ﬂow
limiting thrombus adjacent to the anastomosis of previously bypassed
coronary artery
2. Q-wave MI in the territory of one or more of the treated vessels (LAD, LCX,
RCA) within the ﬁrst 30 days (acute or subacute)
ARC-like deﬁnite GO*
1. SYNTAX protocol deﬁnition as stated in the preceding text
ARC-like probable GOy
1. Any unexplained death within 30 days of graft
2. Any MI that is related to documented acute ischemia in the territory of the
anastomosed graft without angiographic conﬁrmation of GO
ARC-like possible GOz
1. Any unexplained death beyond 30 days
or de novo 3-vessel disease, it was assumed that an MI in any of the 3-vessel territories for 3-vessel
t angiographic conﬁrmation of graft patency was classiﬁed as probable GO. zARC possible GO was
cardial infarction; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; RCA ¼ right
Figure 1 Flow Chart
SYNTAX trial design indicating the number of GO and ST cases using the protocol and ARC/ARC-like deﬁnitions. *In the PCI arm, 871 patients remained in the study at 5 years
(11 withdrew consent and 21 were lost to follow-up/other; in the CABG arm, 805 patients remained in the study at 5 years (50 withdrew consent and 41 were lost to follow-up/
other) (1). ARC ¼ Academic Research Consortium; CABG ¼ coronary artery bypass graft; Def ¼ deﬁnite; EU ¼ Europe; GO ¼ graft occlusion; LM ¼ left main; PCI ¼ percutaneous
coronary intervention; Poss ¼ possible; Prob ¼ probable; RCT ¼ randomized controlled trial; ST ¼ stent thrombosis; US ¼ United States; 3VD ¼ 3-vessel disease.
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2362ARC-like deﬁnitions for GO were retrospectively assessed
in conjunction with the safety reporting data obtained by the
CEC.
Statistical analysis. Continuous variables are expressed
as mean  SD and binary variables as counts and/or
percentages. Time-to-event variables are presented as
Kaplan-Meier (KM) estimates and compared using the log-
rank test. Corrected KM curves were constructed by
removing the ST adjudicated clinical event from the KM
curves (7). Multivariable analyses (Cox regression) were
conducted using the baseline characteristics (Online
Appendix) and the forced enter method (entry criteria
0.05, no exit criteria). There was no departure from the
proportionality of hazards assumption using the global
proportional hazards test based on Schoenfeld residuals (8).
Variables were screened for correlation before entry into
the multivariable model, and none were sufﬁciently corre-
lated to warrant removal. A 2-sided p value <0.05 was
considered signiﬁcant for all tests. All analyses were con-
ducted using SPSS version 20.0 (SPSS Inc., Chicago, Illi-
nois) and SAS system software version 9.2 (SAS Institute,
Cary, North Carolina).Results
Figure 1 shows the study design and frequency of ST and
GO using the SYNTAX protocol and ARC/ARC-like
deﬁnitions. At 5 years, 871 of 903 patients (96.5%) in the
PCI cohort and 805 of 897 patients (89.7%) in the CABG
cohort completed follow-up.
Antiplatelet compliance. Use of aspirin therapy was
signiﬁcantly lower after CABG compared with PCI post-
procedurally (88.5% vs. 96.3%, p < 0.001) and at 1 year
(84.3% vs. 91.2%, p < 0.001) but not at 5 years (85.0% vs.
87.1%, p ¼ 0.24). Use of thienopyridine therapy was
signiﬁcantly lower for CABG post-procedurally (19.4% vs.
96.7%, p < 0.001) and at 1 year (15.0% vs. 71.1%,
p < 0.001) and 5 years (12.1% vs. 32.0%, p < 0.001). Dual
antiplatelet use at 5 years was signiﬁcantly higher with PCI
compared to CABG (9.1% vs. 27.4%, p < 0.001).
Anatomic location of ST and GO at 5 years of
follow-up. Protocol ST was conﬁrmed in 47 subjects with
72 lesions (Fig. 2). Forty-three of 47 subjects had docu-
mented protocol ST conﬁrmed by angiography (62 lesions),
3 subjects had documented protocol ST conﬁrmed by
Figure 2 Coronary Anatomic Location Sites of Protocol ST and Anastomosis Sites of Protocol GO Until 5 Years
The location of per-protocol (clinical presentation with acute coronary syndrome and angiographic/pathological evidence) ST (upper panel) and GO (lower panel) on a lesion-
level basis is shown. ST pertains to the anatomic location in coronary arteries, and GO pertains to the anastomosis site of bypass graft to native coronary arteries. Percentages
are provided, and actual numbers are stated in parentheses. *Denotes ST (listed in the CABG arm on an intention-to-treat basis). N¼ number of patients; L ¼ number of lesions;
other abbreviations as in Figure 1.
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2363autopsy (7 lesions), and this was not recorded in one subject
(3 lesions). Protocol ST occurred more frequently in the left
main (14 of 72; 19.4%) and proximal (37 of 72; 51.4%)
coronary vasculature.
Protocol GO was conﬁrmed in 32 subjects with 41 lesions
(Fig. 2). All 32 subjects had documented protocol GO
conﬁrmed by angiography (41 lesions). Protocol GO
occurred more frequently with grafts anastomosed to the
distal right coronary artery (17 of 41; 42%) compared with
other vessel locations.
ARC/ARC-like deﬁnitions of ST and GO: incidence
and timing. The incidence and timing of ARC/ARC-like
ST and ARC/ARC-like GO are shown in Figures 3 and 4.
At 5 years (KM estimates), there was no signiﬁcant
difference between ARC deﬁnite ST and ARC-like
deﬁnite GO (ARC ST: 6.8% [n ¼ 48]; ARC-like GO:
5.5% [n ¼ 32]; p ¼ 0.34), ARC deﬁnite/probable ST and
ARC-like deﬁnite/probable GO (p ¼ 0.48), and ARC
deﬁnite/probable/possible ST and ARC-like deﬁnite/
probable/possible GO (p ¼ 0.69).
Landmark analyses (Fig. 4) indicated signiﬁcantly more
ARC deﬁnite ST within 30 days (ARC deﬁnite ST: 2.7%[n ¼ 19]; ARC-like deﬁnite GO: 1.0% [n ¼ 6]; p ¼ 0.033)
but not >30 days to 5 years (ARC deﬁnite ST: 4.2%
[n ¼ 29]; ARC-like deﬁnite GO: 4.5% [n ¼ 26]; p ¼ 0.78).
Comparisons of ARC deﬁnite/probable ST and ARC-
like deﬁnite/probable GO showed no signiﬁcant differ-
ences at intervals of 0 to 30 days (p ¼ 0.38), 30 days to
5 years (p ¼ 0.12), and 5 years (p ¼ 0.48). Comparisons of
ARC deﬁnite/probable/ possible ST and ARC-like deﬁnite/
probable/possible GO showed no signiﬁcant differences at
30 days to 5 years (p ¼ 0.33) and 5 years (p ¼ 0.69).
ARC/ARC-like deﬁnitions of ST and GO: adjudicated
clinical outcomes. ARC deﬁnite ST (n ¼ 48) was adju-
dicated by the CEC to be linked to 4 deaths (4 of 48; 8.3%),
11 myocardial infarctions (MIs) (11 of 48; 22.9%), 23 cases
of all-cause revascularization (23 of 48; 47.9%), and 10 cases
with no clinical event (10 of 48; 20.8%). Corrected KM
curves with the clinical events, adjudicated to be associated
with the ARC deﬁnition of ST by the CEC, removed are
shown (Fig. 5). Notably, removal of ARC deﬁnite/probable
ST-related events would have led to a reduction of 5.1% in
cardiac death/MI/all-cause revascularization and a 1.5%
reduction in cardiac death at 5 years.
Figure 3 Comparison of Incidence of ARC Deﬁnition ST and ARC-Like Deﬁnition of GO Until 5 Years
ARC deﬁnite, probable, and possible ST (upper panel) and ARC-like deﬁnite, probable, and possible GO (lower panel) are illustrated. Patient-level data are shown. Abbreviations
as in Figure 1.
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2364ARC-like deﬁnite GO (n ¼ 32) was adjudicated by the
CEC to be linked to 0 deaths, 7 MIs (7 of 32; 21.9%), 21
cases of all-cause revascularization (21 of 32; 65.6%), and 4
cases with no clinical event (4 of 32; 12.5%).
Long-term cardiac mortality associated with the index
ARC/ARC-like ST/GO events. The 5-year relationship
of cardiac mortality to the index ARC ST or ARC-like GO
events is shown (Table 2). At 5 years, ARC deﬁnite ST was
associated with 17 cardiac deaths (17 of 48; 35.4%) (median
number of days to cardiac death: 0; interquartile range:
0 to 16 days; maximum: 321 days) and ARC deﬁnite/
probable ST (n ¼ 75) with 31 cardiac deaths (31 of 75;
41.3%) (median number of days to death: 0; interquartile
range: 0 to 9 days; maximum: 721 days).
Comparatively, at 5 years, ARC-like deﬁnite GO was not
associated with any deaths and ARC-like deﬁnite/probable
GO (n ¼ 53) with 12 cardiac deaths (12 of 52; 23.1%)
(median number of days to death: 0; interquartile range: 0 to
14 days; maximum: 257 days).Multivariable predictors of the ARC deﬁnition of ST.
Table 3 shows multivariable analyses of ARC deﬁnite/
probable ST. Model 1 incorporated components of the
SYNTAX Score and clinical- and procedural-related vari-
ables. Model 2 incorporated the SYNTAX Score and
EuroSCORE. Stent length (in millimeters) and number of
stents implanted were not univariable predictors of early or
late/very late ST.
EARLY ARC ST (WITHIN 30 DAYS). The presence of ULMCA
disease was not a univariable predictor of early ARC ST
(p ¼ 0.84). Lack of post-procedural antiplatelet therapy was
the strongest independent predictor of early ST (p < 0.001),
followed by peripheral vascular disease (p ¼ 0.054), heavy
calciﬁcation (p ¼ 0.054), and prior MI (p ¼ 0.037). Both
the SYNTAX Score (p ¼ 0.086) and additive EuroSCORE
(p ¼ 0.006) were predictors of early ST.
LATE/VERY LATE ARC ST (BEYOND 30 DAYS). The presence of
ULMCA disease showed a trend toward being protective
Figure 4 Kaplan-Meier Estimates of ARC Deﬁnition ST and ARC-Like Deﬁnition GO Until 5 Years
Five-year outcomes (upper panels) and landmark analyses at 0 to 30 days and 31 days to 5 years (lower panels) are illustrated. Log-rank comparisons between ARC and ARC-
like deﬁnitions of ST and GO are shown. Deﬁnite: *p ¼ 0.34, **p ¼ 0.033, ***p ¼ 0.78. Deﬁnite/probable: yp ¼ 0.48, yyp ¼ 0.38, yyyp ¼ 0.12. Deﬁnite/probable/possible:
zp ¼ 0.69, zzp ¼ 0.33. Abbreviations as in Figure 1.
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2365against late/very late ARC ST on univariable analyses (hazard
ratio: 0.61; 95% conﬁdence interval: 0.33 to 1.12; p ¼ 0.10).
The SYNTAX Score was not a univariable predictor of late/
very late ARC ST (p ¼ 0.71). Any baseline angiographically
visible thrombus (p ¼ 0.003) and trifurcation lesion
(p ¼ 0.048) were the strongest independent predictors.
In total, 23 of 903 subjects (2.5%) in the PCI cohort
were reported to have a baseline angiographically visible
thrombus, of which 7 of 23 subjects had ARC ST beyond 30
days (ARC deﬁnite ST: n ¼ 3; ARC possible ST: n ¼ 3;
ARC probable ST: n ¼ 1). Sixty-six of 903 subjects (7.3%)
in the PCI cohort were reported to have trifurcation lesions,
of which 12 of these 66 subjects had ARC ST (ARC
deﬁnite ST: n ¼ 5; ARC probable ST: n ¼ 5; ARC possibleST: n ¼ 2). Three of the 12 cases of ARC ST occurred
in <30 days (2 in subjects with ULMCA disease), and 7
occurred in >30 days (6 in subjects with ULMCA disease).
Multivariable predictors of ARC-like deﬁnite GO. In
the CABG cohort, double left internal mammary artery
(LIMA)/right internal mammary artery (RIMA) and
complete arterial revascularization were reported to be used
in 236 of 897 subjects (26.3%) and 161 of 897 subjects
(17.9%), respectively. On univariable analyses, double
LIMA/RIMA (hazard ratio: 0.86; 95% conﬁdence interval:
0.35 to 2.10; p ¼ 0.74), complete arterial revascularization
(hazard ratio: 0.81; 95% conﬁdence interval: 0.31 to 2.11;
p ¼ 0.67), and ULMCA disease (p ¼ 0.66) were not
statistically associated with a reduction in ARC-like
Figure 5 Corrected Kaplan-Meier Curves for ARC Deﬁnition ST
Kaplan-Meier estimates of cardiac death (black), cardiac death or MI (green), and
cardiac death, MI, or all-cause revascularization (red) according to the ARC deﬁ-
nition (6). Broken lines indicate corrected Kaplan-Meier curves after ST-related
clinical events were excluded. ARC deﬁnite ST is superimposed on the Kaplan-
Meier curves as circles, ARC probable ST as squares, and ARC possible ST as
triangles. Removal of ARC ST-related events would lead to a reduction in cardiac
death/MI/all-cause revascularization (ARC deﬁnite ST: D2.9%; ARC deﬁnite/
probable ST: D5.1%; ARC deﬁnite/probable/possible ST: D8.1%), cardiac death/
MI (ARC deﬁnite ST: D1.3%; ARC deﬁnite/probable ST: D3.8%; ARC deﬁnite/
probable/possible ST: D7.7%), and cardiac death (ARC deﬁnite ST: D0.5%; ARC
deﬁnite/probable ST: D1.5%; ARC deﬁnite/probable/possible ST: D5.5%). MI ¼
myocardial infarction; other abbreviations as in Figure 1.
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2366deﬁnite GO. Any baseline angiographically visible thrombus
(n ¼ 31) (p ¼ 0.41) was not statistically associated with
a reduction in ARC-like deﬁnite GO.
Multivariable analyses indicated that other arterial/venous
conduits (i.e., no LIMA) to the left anterior descending
artery (LAD) (p ¼ 0.050) and the number of grafts (p ¼
0.017) were independent predictors of ARC-like deﬁnite
GO (Table 3). Of subjects with ARC-like deﬁnite GO
(n ¼ 32), 8 had no LIMA to the LAD and 25 were not on
pre-procedural aspirin therapy.Discussion
In this post-hoc study of the randomized, all-comers
SYNTAX trial, the main ﬁndings were as follows. First,
although the incidence of ST and GO at 5 years was similar
using the ARC/ARC-like deﬁnitions, the clinical impact of
ST appeared greater, with a negative impact on short-term
to longer-term mortality. Second, independent predictors
of ST and GO were diverse and related to anatomic or
procedural- or clinical-related factors.
Stent thrombosis. The ﬁndings of ST in the SYNTAX
trial are notable in that early (<30 days) and late/very late
ARC deﬁnite ST (>30 days) were associated with short-
term and long-term mortality. It is important to empha-
size that the actual causes of death are multifactorial and noteasily directly attributed to ST. For example, although lack
of post-procedural antiplatelet therapy was the strongest
independent predictor of ST (Table 3), a recent substudy of
the SYNTAX trial showed that this was of multifactorial
origin (9). Factors precluding antiplatelet administration
were reported to include gastrointestinal bleeding, retro-
peritoneal bleeding from procedure-related femoral vascular
access, coronary perforation, or following surgical bailout for
PCI-related complications. Consequently, directly attrib-
uting ST to mortality is difﬁcult, although it is clear there
was a strong causal link.
In addition, ST most frequently occurred in the left main
and proximal vasculature (>70% of cases). Accordingly, the
impact of ST on mortality is not only related to the
acute consequences of abrupt closure of the treated vessel
but also the short-term to longer-term complications of
MI, including heart failure, arrhythmias, or mechanical
complications (10). Indeed, previously reported analyses of
PCI-treated patients who had post-procedural creatine
kinase levels >2 times the upper limit of normal (with
corroborating elevation of creatine kinase MB fraction) in
the SYNTAX trial were shown to be associated with short-
term (<3 months) and longer-term (2 to 4 years) mortality
(11). Even selecting a time window (e.g., 1 day, 1 week, or 1
month) associating mortality with ST is arbitrary because, as
shown in this study, the interquartile range of cardiac death
after ARC deﬁnite ST ranged from 0 to 16 days, with
a maximum duration of 321 days, and cardiac death was
often of multifactorial origin. Consequently, determining
the potential impact on mortality of newer-generation drug-
eluting stents with proven reductions in ST (12,13) is
difﬁcult to determine in the SYNTAX trial. Comparatively,
potential reductions in ST-related MI and all-cause revas-
cularization were easier to determine, as highlighted in
Figure 5.
Graft occlusion. The present study conﬁrms the estab-
lished supremacy of the long-term durability of LIMA to
the LAD (14). Notably, double LIMA/RIMA was not
associated with a reduced risk of GO on univariable analyses,
despite being undertaken in more than one-fourth (27.6%)
of randomized patients undergoing CABG. It is important
to emphasize that the data related to double LIMA/RIMA
were underpowered to draw any ﬁrm conclusions and are in
contrast to the data in published reports (14,15). Ten-year
follow-up data from a large ongoing randomized trial are
awaited (16).
The ﬁnding of the number of grafts to be an indepen-
dent predictor of GO is consistent with reported studies
in that too extensive surgical revascularization has been
associated with the occurrence of major perioperative
complications and acute MI (17,18). Conversely, the
15-month angiographic substudy of the SYNTAX trial
(19) showed that more than one-fourth (27.2%) of subjects
undergoing CABG had at least one signiﬁcantly diseased
(50% to <100%) or occluded bypass graft at 15 months.
Notably, the reported angiographic loss of the bypass grafts
Table 2 Association of First ARC ST or ARC-Like GO Event With 5-Year Cardiac Death
Incidence
at 5 Yrs (%)
No. of Cardiac
Deaths Post-Event
Until 5 Yrs (%)







SYNTAX trial PCI arm (n ¼ 903)
ST ARC deﬁnition
Classiﬁcation
Deﬁnite 48 (5.3) 17/48 (35.4) 0 0–16 0–321
Probable 27 (3.0) 14/27 (51.9) 0 0–4 0–721
Deﬁnite or probable 75 (8.3) 31/75 (41.3) 0 0–9 0–721
Possible 27 (3.0) 27/27 (100) d d d
Time frame (deﬁnite)
Acute/subacute (30 days) 19 (2.1) 8/19 (42.1) 0 0–6 0–17
Late (31 days to 1 yr) 9 (1.0) 2/9 (22.2) 173 d 25–321
Very late (>1 yr) 20 (2.2) 7/20 (35.0) 0 0–14 0–17
Time frame (deﬁnite/probable)
Acute/subacute (30 days) 24 (2.7) 12/24 (50.0) 0 0–17 0–721
Late (31 days to 1 yr) 15 (1.7) 7/15 (46.7) 0 0–44 0–87
Very late (>1 yr) 36 (4.0) 12/36 (33.3) 0 0–7 0–17
SYNTAX trial CABG arm (n ¼ 897)
GO ARC-like deﬁnition
Classiﬁcation
Deﬁnite 32 (3.6) 0/31 (0) d d d
Probable 21 (2.3) 12/21 (57.1) 0 0–14 0–257
Deﬁnite or probable 53 (5.9) 12/52 (23.1) 0 0–14 0–257
Possible 31 (3.5) 31/31 (100) d d d
Time frame (deﬁnite)
Acute/subacute (30 days) 6 (0.7) 0/6 (0) d d d
Late (31 days to 1 yr) 12 (1.3) 0/12 (0) d d d
Very late (>1 yr) 14 (1.6) 0/13 (0) d d d
Time frame (deﬁnite/probable)
Acute/subacute (30 days) 25 (2.8) 10/25 (40.0) 0 0–6 0–15
Late (31 days to 1 yr) 14 (1.6) 2/14 (14.3) 214 d 170–257
Very late (>1 yr) 14 (1.6) 0/14 (0) d d d
Binary values are given.
Abbreviations as in Table 1. CABG ¼ coronary artery bypass graft; PCI ¼ percutaneous coronary intervention.
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2367was not signiﬁcantly associated with early clinical events
(19), in contrast to GO in the current study (deﬁned in the
context of clinical presentation with acute coronary
syndrome). Reasons to account for the “clinically silent” loss
of bypass grafts have included that they were anastomosed
to functionally insigniﬁcant lesions, with resultant com-
petitive ﬁlling to the native vessel, and were therefore
unnecessary (20).
Study limitations. The present study represents a post-hoc
analysis, and the results should be considered hypothesis
generating. Because ST and GO were deﬁned in the context
of clinical presentation, the true occurrence is likely to be
higher, particularly if the ST occurs in a distal vessel (19). In
addition, saphenous vein grafts have been shown to be
protective in the ﬁrst 7 years; thereafter, mortality and repeat
revascularization have been reported to increase signiﬁ-
cantly, secondary to a gradual loss of graft patency (21).
Given that operative factors were linked to ARC-like
probable GO, ARC-like deﬁnite GO was used for the
multivariable analyses to identify long-term predictors ofGO. As exists with ARC possible ST, ARC-like possible
GO is likely to have a low speciﬁcity in identifying GO.
The exact anatomic segment number of the ST using the
ARC deﬁnite criteria is not available, because this was not
recorded by the CEC. There was limited statistical power
for further subanalyses in patients with ST or GO.
Although multivariable adjustments were performed for
signiﬁcant confounders (p < 0.1), the possibility of other
unmeasured confounders cannot be excluded. The possi-
bility of overﬁtting in the multivariable analyses cannot be
excluded. Because the conﬁdence intervals of these correlates
were relatively narrow, the risk would have been limited (22).
Given the unavoidable differences in follow-up between the
CABG and PCI cohorts, we cannot exclude the possibility
that this may have affected the results.
Conclusions
Although the incidence of ST and GO was similar at 5 years,
the clinical impact of ST appeared greater, with a negative
impact on short-term to longer-term mortality.
Table 3
Multivariable Cox Regression Analyses of Early (<30 Days) and Late/Very Late (30 Days to 5 Years) ARC Deﬁnite/Probable
ST and ARC-Like Deﬁnite GO at 5 Years
Univariable Predictors Multivariable Predictors
HR (95% CI) p Value HR (95% CI) p Value
Early ST (<30 days) (n ¼ 24)
Model 1
Lack of post-procedural antiplatelet therapy (4 of 24, 16.7%) 22.30 (7.61–65.31) <0.001 15.38 (5.20–45.62) <0.001
Peripheral vascular disease (5 of 24, 20.8%) 2.84 (1.06–7.59) 0.038 2.68 (0.98–7.32) 0.054
Any heavy calciﬁcation* (18 of 24, 75.0%) 3.07 (1.22–7.75) 0.017 2.51 (0.98–6.39) 0.054
Prior MI (13 of 24, 54.2%) 2.60 (1.16–5.79) 0.020 2.38 (1.05–5.40) 0.037
Model 2
SYNTAX Score (per 10-point increase) 1.42 (1.05–1.92) 0.025 1.31 (0.96–1.79) 0.086
Additive EuroSCOREy 1.22 (1.08–1.38) 0.001 1.20 (1.05–1.36) 0.006
Late/very late ST (>30 days) (n ¼ 51)
Model 1
Any baseline angiographically visible thrombusz (4 of 51, 7.8%) 3.74 (1.35–10.37) 0.011 4.86 (1.73–13.65) 0.003
Any circumﬂex lesion (49 of 51, 96.1%) 4.27 (1.04–17.55) 0.044 3.08 (0.73–13.01) 0.13
Any trifurcation lesion (7 of 51, 13.7%) 2.00 (0.90–4.43) 0.089 2.27 (1.01–5.12) 0.048
Any right coronary artery lesion (47 of 51, 92.2%) 2.72 (0.98–7.53) 0.055 2.18 (0.76–6.23) 0.15
Unstable angina (21 of 51, 41.2%) 1.85 (1.07–3.21) 0.028 1.49 (0.77–2.87) 0.23
Prior MI (24 of 51, 47.1%) 2.04 (1.19–3.52) 0.01 1.68 (0.94–2.99) 0.079
Additive EuroSCOREy 1.09 (0.99–1.20) 0.076 1.02 (0.91–1.16) 0.72
Model 2
SYNTAX Score (per 10-point increase) 0.96 (0.75–1.21) 0.71 d d
Additive EuroSCOREy 1.09 (0.99–1.20) 0.076 d d
ARC-like deﬁnite GO (n ¼ 32)
No LIMA to LAD (8 of 32, 25.8%) 2.68 (1.20–5.98) 0.017 2.30 (1.00–5.28) 0.050
Number of grafts per patienty 1.78 (1.08–2.93) 0.023 1.87 (1.12–3.12) 0.017
Lack of pre-procedural aspirin (25 of 32, 78.1%) 2.34 (1.01–5.41) 0.047 1.87 (0.79–4.40) 0.15
Peripheral vascular disease (6 of 32, 18.8%) 2.58 (1.06–6.27) 0.036 1.47 (0.54–4.00) 0.45
Body mass indexy (kg/m2) 0.92 (0.84–1.00) 0.062 0.93 (0.85–1.02) 0.13
Previous MI (5 of 32, 15.6%) 0.38 (0.15–0.98) 0.046 0.38 (0.15–1.01) 0.052
Incidence of variables is provided in parentheses. *Multiple persisting opaciﬁcations of the coronary wall visible in more than one projection surrounding the complete lumen of the coronary artery at the site
of the lesion. yContinuous variables per unit increase. zSpheric, ovoid, or irregular intraluminal ﬁlling defect or lucency surrounded on 3 sides by contrast medium seen just distal or within the coronary
stenosis in multiple projections or a visible embolization of intraluminal material downstream.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LIMA ¼ left internal mammary artery; other abbreviations as in Table 1.
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APPENDIX
For an expanded Methods section as well as supplemental tables and
ﬁgures, please see the online version of this article.
